It is important to note that APQ4 autoantibody was present in only about 65% of NMO patients, and completely absent in the serum of MS patients, whereas KIR4.1 autoantibody was suggested to be present in about half of MS patients (Srivastava et al., 2012). This evidence concerns the gene KCNJ10 and myeloid sarcoma.